These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 1784098

  • 21. Synergistic generation of tumoricidal macrophages by muroctasin and interferon-gamma.
    Nagao S, Sato K, Osada Y.
    Arzneimittelforschung; 1988 Jul; 38(7A):999-1002. PubMed ID: 3142490
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Enhancement of serum antibody production in mice by oral administration of lipophilic derivatives of muramyl peptides and bacterial lipopolysaccharides with bovine serum albumin.
    Ogawa T, Kotani S, Shimauchi H.
    Methods Find Exp Clin Pharmacol; 1986 Feb; 8(2):117-25. PubMed ID: 3713372
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Restorative activity of muroctasin on leukopenia associated with anticancer treatment.
    Tsubura E, Nomura T, Niitani H, Osamura S, Okawa T, Tanaka M, Ota K, Nishikawa H, Masaoka T, Fukuoka M.
    Arzneimittelforschung; 1988 Jul; 38(7A):1070-4. PubMed ID: 3190800
    [Abstract] [Full Text] [Related]

  • 27. Protective effect of neoglycoprotein-conjugated muramyl dipeptide against Leishmania donovani infection: the role of cytokines.
    Sarkar K, Das PK.
    J Immunol; 1997 Jun 01; 158(11):5357-65. PubMed ID: 9164956
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Relationship of anti-tuberculous protection to lung granuloma produced by intravenous injection of synthetic 6-O-mycoloyl-N-acetylmuramyl-L-alanyl-D-isoglutamine with or without specific antigens.
    Yamamoto K, Kakinuma M, Kato K, Okuyama H, Azuma I.
    Immunology; 1980 Aug 01; 40(4):557-64. PubMed ID: 7000685
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Further study on relationship of anti-tuberculous protection to lung granulomata produced by intravenous injections of synthetic 6-0-mycoloyl-N-acetyl-muramyl-L-alanyl-D-isoglutamine with or without specific antigens.
    Yamamoto K, Kato K, Kakinuma M, Okuyama H, Azuma I.
    Immunology; 1982 Jun 01; 46(2):473-9. PubMed ID: 7044961
    [Abstract] [Full Text] [Related]

  • 40. Effect of MDP-Lys(L18), a derivative of MDP, on enhancing host resistance against Hantaan virus infection in newborn mice.
    Yoo YC, Yoshimatsu K, Hatsuse R, Tamura M, Yoshida R, Tono-oka S, Arikawa J, Azuma I.
    Vaccine; 1995 Oct 01; 13(14):1300-5. PubMed ID: 8585284
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.